Key terms
About PCRX
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PCRX news
Apr 09
6:16am ET
Understanding Key Factors Behind Pacira Pharmaceuticals’ Analyst Rating
Apr 08
9:50pm ET
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)
Mar 13
7:24am ET
Pacira granted RMAT designation for PCRX-201
Mar 07
4:50am ET
Pacira assumed with an Overweight at JPMorgan
Mar 03
12:27pm ET
Pacira price target lowered to $40 from $50 at Barclays
Mar 03
10:15am ET
Buy Rating Affirmed for Pacira Pharmaceuticals Amid Strategic Growth Initiatives and Management Restructuring
Mar 01
9:30am ET
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Pacira Pharmaceuticals (PCRX)
Mar 01
7:35am ET
Truist Financial Keeps Their Buy Rating on Pacira Pharmaceuticals (PCRX)
Mar 01
7:26am ET
RBC Capital Sticks to Its Buy Rating for Pacira Pharmaceuticals (PCRX)
Feb 29
4:25pm ET
Strong Buy Rating for Pacira Pharmaceuticals Amid Favorable NOPAIN Act Implications and Strategic Growth Initiatives
Feb 29
8:12am ET
Pacira Pharmaceuticals CFO Transition and Financial Update
Feb 29
8:04am ET
Pacira reports Q4 EPS 89c, consensus 88c
Feb 15
8:39am ET
Pacira announces publication of study of EXPAREL
Feb 07
3:16pm ET
Buy Rating for Pacira Pharmaceuticals: Strategic Partnerships and Market Opportunities Fuel Growth Outlook
Feb 07
8:16am ET
Pacira awarded Brand Pharmaceuticals agreement with Premier
Jan 29
5:07am ET
Barclays Sticks to Its Buy Rating for Pacira Pharmaceuticals (PCRX)
Jan 26
6:20am ET
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Repare Therapeutics (RPTX)
Jan 26
6:06am ET
Pacira named a top pick for 2024 at H.C. Wainwright
No recent press releases are available for PCRX
PCRX Financials
Key terms
Ad Feedback
PCRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PCRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range